# OnCo record venetoclax (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/venetoclax/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "venetoclax" ;
  schema:name "Venetoclax"@en ;
  schema:description "A pill that removes the survival shield from leukaemia cells, enabling chemotherapy-free, time-limited treatment for CLL."@en ;
  schema:url <https://onco.cc/drugs/venetoclax/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Venetoclax> ;
  owl:sameAs <http://www.wikidata.org/entity/Q23671272> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Venetoclax>, <https://doi.org/10.1158/2159-8290.CD-18-1119> ;
  onco:status "approved" ;
  onco:modality "Small-molecule BCL-2 inhibitor" ;
  schema:alternateName "Venclexta" ;
  onco:approval "US 2016: CLL with 17p deletion", "US 2018: AML with azacitidine/decitabine/LDAC in unfit patients" ;
  onco:acceleratedApproval "US 2016-04-11: Chronic lymphocytic leukemia with 17P deletion as detected by an FDA-approved test, after at least one prior therapy", "US 2018-11-21: In combination with azacitidine or decitabine or low-dose cytarabine for newly-diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy" ;
  onco:acceleratedApprovalConfirmed "US 2018-06-08: Chronic lymphocytic leukemia with 17P deletion as detected by an FDA-approved test, after at least one prior therapy", "US 2020-10-16: In combination with azacitidine or decitabine or low-dose cytarabine for newly-diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy" ;
  onco:cancers <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/aml-older-unfit/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/bcl2-inhibitors/> ;
  onco:targets <https://onco.cc/targets/bcl2/> ;
  onco:companies <https://onco.cc/companies/abbvie/>, <https://onco.cc/companies/roche-genentech/> ;
  onco:terms <https://onco.cc/terms/lymphoma-bio-antigen-escape/> ;
  onco:trials <https://onco.cc/trials/nct03844048/>, <https://onco.cc/trials/nct03539744/>, <https://onco.cc/trials/nct03314181/>, <https://onco.cc/trials/nct04068597/>, <https://onco.cc/trials/nct05951959/>, <https://onco.cc/trials/nct07387471/>, <https://onco.cc/trials/nct06115135/>, <https://onco.cc/trials/nct04988555/>, <https://onco.cc/trials/nct02899052/>, <https://onco.cc/trials/nct06382168/>, <https://onco.cc/trials/nct05673057/>, <https://onco.cc/trials/nct07007312/>, <https://onco.cc/trials/nct06943872/>, <https://onco.cc/trials/nct04588922/>, <https://onco.cc/trials/nct05947851/>, <https://onco.cc/trials/nct02966756/>, <https://onco.cc/trials/nct07277231/>, <https://onco.cc/trials/nct06428019/>, <https://onco.cc/trials/nct06846671/>, <https://onco.cc/trials/nct04229979/>, <https://onco.cc/trials/nct04256317/>, <https://onco.cc/trials/nct07743112/>, <https://onco.cc/trials/nct05211570/>, <https://onco.cc/trials/nct07154264/>, <https://onco.cc/trials/nct04581512/>, <https://onco.cc/trials/nct05520567/>, <https://onco.cc/trials/nct04965493/>, <https://onco.cc/trials/nct07581002/>, <https://onco.cc/trials/nct07024706/>, <https://onco.cc/trials/nct04086264/>, <https://onco.cc/trials/nct05963074/>, <https://onco.cc/trials/nct05057494/>, <https://onco.cc/trials/nct04895436/>, <https://onco.cc/trials/nct07255872/>, <https://onco.cc/trials/nct07520006/>, <https://onco.cc/trials/nct06456463/>, <https://onco.cc/trials/nct06524375/> ;
  onco:people <https://onco.cc/people/peter-hillmen/> .